reports
Paycom Software Inc: 1 director
A director at Paycom Software Inc sold 30,000 shares at 265.228USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Ru...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 30, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards c...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
TLYS TILLYS
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
MCY MERCURY GENERAL CORPORATION
LTRX LANTRONIX INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
FLO FLOWERS FOODS INC.
BUSE FIRST BUSEY CORPORATION
VFF VILLAGE FARMS INTERNATIONAL IN
EXP EAGLE MATERIALS INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BDL FLANIGAN'S ENTERPRISES INC.
UIHC UNITED INSURANCE HOLDINGS CORP.
BXC BLUELINX HOLDINGS
HAIN THE HAIN CELESTIAL GROUP
GPMT INC.
NHF GRANITE POINT MORTGAGE TRUST INC.
BCBP NEXPOINT CREDIT STRATEGIES FUN
BRT BCB BANCORP INC.
PMTS BRT APARTMENTS
MPB CPI CARD GROUP
NWPP MID PENN BANCORP INC.
RFL NEW PEOPLES BANKSHARES INC.
KKR RAFAEL HOLDINGS CL B
REZI KKR & CO. INC.
LBSRD RESIDEO TECHNOLOGIES
XRX INC.
VLA LIBERTY STAR URANIUM & METALS
INNV XEROX HOLDINGS CORPORATION
ALIT ARBOR METALS
TCRX INNOVAGE HOLDING
UDMY ALIGHT
BHRB INC. / DELAWARE
OPAL FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
PRME UDEMY INC
VFC BURKE & HERBERT BANK & TR/VA
UHG OPAL FUELS INC
HYLN PRIME MEDICINE INC
NCDL VF CORPORATION
PROP UNITED HOMES GROUP INC
FIP HYLIION HOLDINGS CORP.
TXO NUVEEN CHURCHILL DIRECT LENDING CORP
NEO PRAIRIE OPERATING CO.
JEQ FTAI INFRASTRUCTURE INC
MORNINGSTAR PARTNERS
L.P.
NEO CORPORATE PUBLIC COMPANY LIMITED
THE JAPAN EQUITY FUND
INC.
- Jonathan Moreland
TLYS TILLYS
PEB PEBBLEBROOK HOTEL TRUST
MCY MERCURY GENERAL CORPORATION
FLO FLOWERS FOODS INC.
CE CELANESE CORPORATION
BUSE FIRST BUSEY CORPORATION
NHF NEXPOINT CREDIT STRATEGIES FUN
ULBI ULTRALIFE
ADV ADVANTAGE SOLUTIONS INC (A)
VSTS_w VESTIS CORPORATION
SDHC SMITH DOUGLAS HOMES CORP
FIP FTAI INFRASTRUCTURE INC
NEO NEO CORPORATE PUBLIC COMPANY LIMITED
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydroc...
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution • KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million DEER PARK, Ill., May 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Foo...
The Tile Shop to Debut Exclusive Tile Collection With Nate Berkus
The Tile Shop to Debut Exclusive Tile Collection With Nate Berkus The Tile Shop x Nate Berkus will arrive at all U.S. Tile Shop showrooms and tileshop.com starting fall 2026. MINNEAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- The Tile Shop () today announced a new collaboration with award-winning designer Nate Berkus. The Tile Shop x Nate Berkus, available exclusively at The Tile Shop, will debut in Tile Shop showrooms and on tileshop.com in early fall 2026. The Tile Shop x Nate Berkus collection will feature floor and wall tiles, in a diverse range of materials and shapes, anchored in a pa...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
PLUG PLUG POWER INC.
MAIN MAIN STREET CAPITAL CORPORATION
PATK PATRICK INDUSTRIES INC.
ELY CALLAWAY GOLF COMPANY
UEIC UNIVERSAL ELECTRONICS INC.
UIHC UNITED INSURANCE HOLDINGS CORP.
FLWS 1-800-FLOWERS.COM CL A
SNDX SYNDAX PHARMACEUTICALS
NNBR NN
OCSL INC.
MPB OAKTREE SPECIALTY LENDING CORPORATION
ENR MID PENN BANCORP INC.
ZYME EDGEWELL PERSONAL CARE COMPANY
ARQT ZYMEWORKS INC.
HQL ARCUTIS BIOTHERAPEUTICS
ADV INC.
CVRX TEKLA LIFE SCIENCES INVESTORS
SRPT ADVANTAGE SOLUTIONS INC (A)
DMA CVRX
SUNS INC.
EVM SAREPTA THERAPEUTICS
TXO INC.
GF DESTRA MULTI ALTERNATIVE FUND
FG SUNRISE REALTY TRUST
IAE EATON VANCE INSD CALIF MUN BD FD
MORNINGSTAR PARTNERS
L.P.
THE NEW GERMANY FUND
INC.
F AND G ANNUITIES AND LIFE
INC.
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, and David Krempa, Chief Business Officer, will participate in two upcoming investor conferences as follows: The 25th Annual B. Riley Securities Investor ConferenceDate: Thursday, May 22, 2025, at ...
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic ...
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in combination therapy BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the acceptance of two abstra...
- Jonathan Moreland
OEC ORION ENGINEERED CARBONS SA
LTRX LANTRONIX INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
NEWT NEWTEK BUSINESS SERVICES INC.
HTLD HEARTLAND EXPRESS INC.
UEIC UNIVERSAL ELECTRONICS INC.
VSH VISHAY INTERTECHNOLOGY INC.
FLL FULL HOUSE RESORTS INC.
FLWS
NINE 1-800-FLOWERS.COM CL A
CNX NINE ENERGY SERVICE INC
A2H9KJ CONSOL ENERGY INC.
TCPC NEO PERFORMANCE MATERIAL
MIDD BLACKROCK TCP CAPITAL CORP.
ENR THE MIDDLEBY CORPORATION
PHAT EDGEWELL PERSONAL CARE COMPANY
DLHC PHATHOM PHARMACEUTICALS
MINM DALEIGH HOLDINGS CORP
STGW MINIM
NVCT INC.
PFHC STAGWELL INC
RXO_w NUVECTIS PHARMA INC
FTK PROFRAC HLDG CORP
NCDL RXO INC
DMA FLOTEK INDUSTRIES INC.
GF NUVEEN CHURCHILL DIRECT LENDING CORP
IAE DESTRA MULTI ALTERNATIVE FUND
THRM THE NEW GERMANY FUND
AESI INC.
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
SOLTA MEDICAL, INC
ATLAS ENERGY SOLUTIONS INC.
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully diluted EPS of $0.07, and Adjusted EBITDA of $3.7 millionRelaunched pediatric endocrinology biologic INCRELEX® in the U.S. and out-licensed international rightsEstablished Wilson disease franchise with the acquisition and relaunch of GALZIN® (zinc acetate) capsules and the introduction of p...
The Tile Shop Reports First Quarter 2025 Results
The Tile Shop Reports First Quarter 2025 Results MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles today announced results for its first quarter ended March 31, 2025. First Quarter 2025 Summary Net Sales Decreased 4.1%Comparable Store Sales Decreased 4.0% Gross Margin of 66.0%Net Income of $0.2 Million and Adjusted EBITDA of $4.6 MillionNo Debt Outstanding and $27.1 million of Cash at Quarter-End Management Commentary – Cabell Lolmaugh, CEO “While hou...
Certara Reports First Quarter 2025 Financial Results
Certara Reports First Quarter 2025 Financial Results Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue w...
The Tile Shop to Host First Quarter 2025 Earnings Conference Call
The Tile Shop to Host First Quarter 2025 Earnings Conference Call MINNEAPOLIS, May 01, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone tiles, man-made and luxury vinyl tiles, setting and maintenance materials, and related accessories, today announced that the Company will release financial results for the first quarter ended March 31, 2025, at 7:00 a.m. Eastern Time on Thursday, May 8, 2025. The Company will host a conference call via webcast for investors and other interested parties beginning at 9:00 a.m. Eastern T...
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on...
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In* (Audio Only) Webcast: ...
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Pr...
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates 4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system,...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
CDXS CODEXIS
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
BANC BANC OF CALIFORNIA INCORPORATED
MRTN MARTEN TRANSPORT LTD.
AVTR AVANTOR
TCBX INC.
GLSI THIRD COAST BANCSHARES INC
JMSB GREENWICH LIFESCIENCES INC
NBBK JOHN MARSHALL BANCORP INC
BHRB NB BANCORP INC.
DMA BURKE HERBERT FINANCIAL SERVICES CORP
DESTRA MULTI ALTERNATIVE FUND
Certara to Participate in Upcoming Investor Conferences
Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 Healthcare ConferenceDate and Time: Tuesday, May 13 at 3:40 p.m. PT William Blair 45th Annual Growth Stock ConferenceDate and Time: Wednesday, June 4 at 12:40 p.m. CT Live webcasts for each of the conferences will be available on Certara’s investor relations website at and will be availa...
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopres...
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) - NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-...
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and ...
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.